Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan by Chen Pei, Lin Juei-Jueng, Lu Chin-Song, Ong Cheung-Ter, Hsieh Peiyuan F, Yang Chih-Chao, Tai Chih-Ta, Wu Shey-Lin, Lu Cheng-Hsien, Hsu Yung-Chu, Yu Hsiang-Yu, Ro Long-Sun, Lu Chung-Ta, Chu Chun-Che, Tsai Jing-Jane, Su Yu-Hsiang, Lan Sheng-Hsing, Sung Sheng-Feng, Lin Shu-Yi, Chuang Hui-Ping, Huang Li-Chen, Chen Ying-Ju, Tsai Pei-Joung, Liao Hung-Ting, Lin Yu-Hsuan, Chen Chien-Hsiun, Chung Wen-Hung, Hung Shuen-Iu, Wu Jer-Yuarn, Chang Chi-Feng, Chen Luke, Chen Yuan-Tsong, Shen Chen-Yang, Taiwan SJS Consortium in The New England journal of medicine (2011).

[PMID: 21428768] PubMed


Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

Dosing Annotation for carbamazepine and HLA-B

Prospective screening for HLA-B*15:02 significantly decreased the incidence of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) (p<0.001)
Prospective screeningHistorical incidence
HLA-B*15:02 positive patients excluded from treatment, HLA-B*15:02 negative patients received carbamazepineExpected number of (SJS/TEN) cases given historical incidence
0 patients developed SJS/TEN10 patients estimated to develop SJS/TEN based on historical incidence

Number: 4877

Ethnicity: Taiwanese